These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 26319783)

  • 1. Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR.
    Drandi D; Kubiczkova-Besse L; Ferrero S; Dani N; Passera R; Mantoan B; Gambella M; Monitillo L; Saraci E; Ghione P; Genuardi E; Barbero D; Omedè P; Barberio D; Hajek R; Vitolo U; Palumbo A; Cortelazzo S; Boccadoro M; Inghirami G; Ladetto M
    J Mol Diagn; 2015 Nov; 17(6):652-60. PubMed ID: 26319783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Droplet Digital PCR for Minimal Residual Disease Detection in Mature Lymphoproliferative Disorders.
    Drandi D; Ferrero S; Ladetto M
    Methods Mol Biol; 2018; 1768():229-256. PubMed ID: 29717447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.
    Pott C; Brüggemann M; Ritgen M; van der Velden VHJ; van Dongen JJM; Kneba M
    Methods Mol Biol; 2019; 1956():199-228. PubMed ID: 30779036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis between RQ-PCR and digital droplet PCR of BCL2/IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma.
    Cavalli M; De Novi LA; Della Starza I; Cappelli LV; Nunes V; Pulsoni A; Del Giudice I; Guarini A; Foà R
    Br J Haematol; 2017 May; 177(4):588-596. PubMed ID: 28419517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Common consensus LNA probe for quantitative PCR assays in cancer: vehicles for minimal residual disease detection in t(11;14) and t(14;18) positive malignant lymphomas.
    Sørensen CD; Jørgensen JM; Nederby L; Hokland P; Nyvold CG
    J Immunol Methods; 2014 Apr; 406():131-6. PubMed ID: 24631717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms.
    Ferrero S; Drandi D; Mantoan B; Ghione P; Omedè P; Ladetto M
    Hematol Oncol; 2011 Dec; 29(4):167-76. PubMed ID: 22678691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Droplet Digital PCR Is a Reliable Tool for Monitoring Minimal Residual Disease in Acute Promyelocytic Leukemia.
    Brunetti C; Anelli L; Zagaria A; Minervini A; Minervini CF; Casieri P; Coccaro N; Cumbo C; Tota G; Impera L; Orsini P; Specchia G; Albano F
    J Mol Diagn; 2017 May; 19(3):437-444. PubMed ID: 28268092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma.
    Della Starza I; De Novi LA; Cavalli M; Novelli N; Soscia R; Genuardi E; Mantoan B; Drandi D; Ferrante M; Monitillo L; Barbero D; Ciabatti E; Grassi S; Bomben R; Degan M; Gattei V; Galimberti S; Di Rocco A; Martelli M; Cortelazzo S; Guarini A; Foà R; Ladetto M; Ferrero S; Del Giudice I;
    Hematol Oncol; 2020 Dec; 38(5):698-704. PubMed ID: 32816326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis between RQ-PCR and digital-droplet-PCR of immunoglobulin/T-cell receptor gene rearrangements to monitor minimal residual disease in acute lymphoblastic leukaemia.
    Della Starza I; Nunes V; Cavalli M; De Novi LA; Ilari C; Apicella V; Vitale A; Testi AM; Del Giudice I; Chiaretti S; Foà R; Guarini A
    Br J Haematol; 2016 Aug; 174(4):541-9. PubMed ID: 27172403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR.
    Pott C; Brüggemann M; Ritgen M; van der Velden VH; van Dongen JJ; Kneba M
    Methods Mol Biol; 2013; 971():175-200. PubMed ID: 23296964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders.
    Ladetto M; Brüggemann M; Monitillo L; Ferrero S; Pepin F; Drandi D; Barbero D; Palumbo A; Passera R; Boccadoro M; Ritgen M; Gökbuget N; Zheng J; Carlton V; Trautmann H; Faham M; Pott C
    Leukemia; 2014 Jun; 28(6):1299-307. PubMed ID: 24342950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang.
    Gimenez E; Chauvet M; Rabin L; Puteaud I; Duley S; Hamaidia S; Bruder J; Rolland-Neyret V; Le Gouill S; Tournilhac O; Voog E; Maisonneuve H; Jacob MC; Leroux D; Béné MC; Formisano-Tréziny C; Gabert J; Gressin R; Callanan MB
    Br J Haematol; 2012 Jul; 158(2):186-197. PubMed ID: 22626453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal residual disease detection by mutation-specific droplet digital PCR for leukemia/lymphoma.
    Shirai R; Osumi T; Keino D; Nakabayashi K; Uchiyama T; Sekiguchi M; Hiwatari M; Yoshida M; Yoshida K; Yamada Y; Tomizawa D; Takae S; Kiyokawa N; Matsumoto K; Yoshioka T; Hata K; Hori T; Suzuki N; Kato M
    Int J Hematol; 2023 Jun; 117(6):910-918. PubMed ID: 36867356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transferring measurable residual disease measurement in pediatric acute lymphoblastic leukemia from quantitative real-time PCR to digital droplet PCR.
    Luib L; Kreyenberg H; Michaelis S; Handgretinger R; Mezger M
    Pediatr Transplant; 2023 Jun; 27(4):e14483. PubMed ID: 36750990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Minimal residual disease in follicular and mantle cell lymphoma. Detection using quantitative molecular monitoring of circulating lymphoma cells].
    Schüler F; Hirt C; Dölken L; Krüger W; Dölken G
    Dtsch Med Wochenschr; 2005 Sep; 130(38):2130-4. PubMed ID: 16172952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Droplet Digital PCR Is a Robust Tool for Monitoring Minimal Residual Disease in Adult Philadelphia-Positive Acute Lymphoblastic Leukemia.
    Coccaro N; Anelli L; Zagaria A; Casieri P; Tota G; Orsini P; Impera L; Minervini A; Minervini CF; Cumbo C; Parciante E; Carluccio P; Brunetti C; Specchia G; Albano F
    J Mol Diagn; 2018 Jul; 20(4):474-482. PubMed ID: 29625246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical value of flow cytometric immunophenotypic analysis for minimal residual disease detection in autologous stem-cell products of follicular and mantle cell lymphomas.
    Kato H; Yamamoto K; Oki Y; Ine S; Taji H; Chihara D; Kagami Y; Seto M; Morishima Y
    Leukemia; 2012 Jan; 26(1):166-9. PubMed ID: 21818114
    [No Abstract]   [Full Text] [Related]  

  • 18. Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial.
    Galimberti S; Luminari S; Ciabatti E; Grassi S; Guerrini F; Dondi A; Marcheselli L; Ladetto M; Piccaluga PP; Gazzola A; Mannu C; Monitillo L; Mantoan B; Del Giudice I; Della Starza I; Cavalli M; Arcaini L; Tucci A; Palumbo GA; Rigacci L; Pulsoni A; Vitolo U; Boccomini C; Vallisa D; Bertoldero G; Gaidano G; Musto P; Petrini M; Federico M
    Clin Cancer Res; 2014 Dec; 20(24):6398-405. PubMed ID: 25316810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
    Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A
    Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of tumor-specific marker for minimal residual disease in multiple myeloma patients.
    Sedlarikova L; Kubiczkova L; Kryukov F; Pelcova J; Adam Z; Pour L; Hajek R; Sevcikova S
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Dec; 159(4):554-61. PubMed ID: 24993743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.